Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Piperacillin Sodium,Tazobactam Sodium
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
B. Braun Gains FDA Approval for DUPLEX Delivery of Piperacillin Combo
Details : Piperacillin, a penicillin-class antibacterial, and Tazobactam, a beta-lactamase inhibitor, in the DUPLEX Drug Delivery System and Sodium Chloride, indicated for Intra-abdominal infections.
Product Name : Piperacillin and Tazobactam for Injection
Product Type : Antibiotic
Upfront Cash : Inapplicable
April 09, 2025
Lead Product(s) : Piperacillin Sodium,Tazobactam Sodium
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cefazolin Sodium,Dextrose
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
B. Braun Launches Ready-to-Activate Cefazolin 3 Gram Pre-Mix in DUPLEX® Containers
Details : Cefazolin sodium is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. It is indicated for several infections, like respiratory, urinary infections in adult and pediatric.
Product Name : Cefazolin Sodium Injection
Product Type : Antibiotic
Upfront Cash : Inapplicable
March 24, 2025
Lead Product(s) : Cefazolin Sodium,Dextrose
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Levetiracetam
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
B. Braun Launches Levetiracetam in Sodium Chloride Injection Portfolio
Details : Levetiracetam is indicated for adjunctive therapy in the treatment of Partial onset seizures in patients one month of age and older with epilepsy.
Product Name : Levetiracetam-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 28, 2024
Lead Product(s) : Levetiracetam
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tissue-engineered Autologous Outer Root Sheath Keratinocyte
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Approved FDF
Sponsor : Healiva
Deal Size : Undisclosed
Deal Type : Acquisition
Healiva® Acquires Critical Cell Therapy Manufacturing Assets From B. Braun
Details : The acquisition includes a qualified cell bank, which is essential for the GMP-compliant manufacturing of Healiva’s first cell therapy product, EpiDex®: an autologous epidermis derived from the patient’s own hair cells.
Product Name : Epidex
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
November 21, 2022
Lead Product(s) : Tissue-engineered Autologous Outer Root Sheath Keratinocyte
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Approved FDF
Sponsor : Healiva
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Cefazolin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmacokinetics and Safety of Cefazolin 3gm DUPLEX in Adults
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
January 25, 2022
Lead Product(s) : Cefazolin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Chloroprocaine
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Recipient : Oregon Health and Science University
Deal Size : Inapplicable
Deal Type : Inapplicable
Comparison of Clorotekal and Bupivacaine for Short Obstetric Surgery
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 30, 2019
Lead Product(s) : Chloroprocaine
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Recipient : Oregon Health and Science University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Omega-6
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
The HOME Study (HPN With OMEGA-3)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 14, 2017
Lead Product(s) : Omega-6
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cefazolin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety of 1 g and 2 g of Cefazolin in Pediatric Subjects
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
July 27, 2017
Lead Product(s) : Cefazolin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nutricomp Drink Plus
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Acceptability Study on Nutricomp® Drink Plus Fibre in Adults
Details : Undisclosed
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
January 09, 2017
Lead Product(s) : Nutricomp Drink Plus
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Gelaspan
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study on the Efficacy and Safety of Gelaspan
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 21, 2016
Lead Product(s) : Gelaspan
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable